Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Change in Account Payables (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Change in Account Payables for 10 consecutive years, with -$1.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 741.41% to -$1.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.0 million, a 178.92% increase, with the full-year FY2024 number at -$279000.0, up 94.4% from a year prior.
  • Change in Account Payables was -$1.9 million for Q3 2025 at Rein Therapeutics, down from $4.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.9 million in Q2 2025 to a low of -$3.7 million in Q4 2023.
  • A 5-year average of -$101315.8 and a median of $19000.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: surged 573.96% in 2021, then tumbled 4289.47% in 2022.
  • Rein Therapeutics' Change in Account Payables stood at $178000.0 in 2021, then soared by 335.39% to $775000.0 in 2022, then tumbled by 583.35% to -$3.7 million in 2023, then surged by 95.52% to -$168000.0 in 2024, then tumbled by 1033.93% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Change in Account Payables are -$1.9 million (Q3 2025), $4.9 million (Q2 2025), and $238000.0 (Q1 2025).